Bulley, Margaret

From:	labclientservice			
Sent:	Monday, October 15, 2018 5:28 PM			
То:	GME PC; Ortolf, Barbara; Salvatore, Alicia; Regional Physicians Group Directors of			
	Operations; Regional Physician Group Practice Managers; Regional Physician Group			
	Physicians; CPUP DOO's; CPUP Business Administrators; CPUP Managers; Allen,			
	Kathleen; Viola, Kathy; Redmond, Cassandra I; Khemraj, Darci; Major, Katherine			
Cc:	Fogt, Franz; Atweh, Mahmoud (Michael); Hunt, William; Gualtieri, Roseann; Murphy,			
	Alice M; Shaw, Leslie; Milone, Michael; Gardiner, JoAnn; Milano, Joe; Nachamkin, Irving;			
	Mincarelli, Deborah; Bulley, Margaret; Danoski, Daniel; McLaughlin, Cara;Leonard,			
	Sarah; Vespasiani, Lynn; Long, Jeff; Acker, David; Agront, Sarita; Bahar, Wael Y; Mcaleer,			
	Diane S; Macchione, Gerald; Kim, Sharon; Metheny, Robert			
Subject:	PENN MEDICINE - New Pain Management Drug Analysis test procedure			
Attachments:	Pain Management testing program communication to UPHS clinical staff v2.docx			



University of Pennsylvania Health System

To: Members of UPHS Clinical Staff

From: Leslie M Shaw, PhD and Michael C Milone, MD, PhD

Date: October 22, 2018

Re: New Pain Management Drug Analysis test procedure

New Pain Management Drug Analysis procedure effective October 22, 2018

The Toxicology laboratory has validated and implemented a new Pain Management Drug Analysis test procedure using liquid chromatography-tandem mass spectrometry (LC-MSMS) that will detect the presence of 44 drugs and metabolites in urine including 11 drugs of abuse, 17 opioids and 16 benzodiazepines (see table below).

This testing procedure replaces and expands upon the current Pain Management tests that includes a combination of urine drug testing using 10 immunoassays(DA10), the Opiate confirmatory testing by LC-MSMS and additional confirmation testing by GC-MS. The new Pain Management Drug Analysis procedure has a high degree of specificity and sensitivity, for all of the 44 drugs and metabolites and uses a single LC-MSMS test methodology.

Result reporting includes the cutoff concentration values for each of the 44 analytes. The 11 drugs of abuse are reported as qualitative results similar to the current immunoassay-based screening approach. Opioids and benzodiazepines will be reported with quantitative concentration results which should aid in result interpretation. Ethanol testing is done as in the past using a specific alcohol dehydrogenase enzyme assay and the report will include ethanol presence or absence as well as its cutoff value. For many of the analytes, standardized interpretative comments will also be provided.

The enhanced sensitivity of the LC-MSMS methodology provides for lowered cutoff concentrations for most of the 44 analytes as compared to the immunoassay-based cutoffs. These lower detection thresholds may result in changes to typical urine drug screening results for some patients undergoing monitoring when compared with the immunoassay-based screening approach.

EPIC Ordering information:

TEST CODE is DAPM; TEST NAME is DRUG ANALYSIS, PAIN MANAGEMENT

Please feel free to contact us regarding the new Pain Management Drug Analysis testing procedure.

Contact information: Clinical Chemistry resident:215-980-9770 Leslie M Shaw Email: <u>Les.Shaw@uphs.upenn.edu</u> Cell phone: 267-251-8901

Michael C Milone Email: <u>Michael.Milone@uphs.upenn.edu</u> Cell phone: 215-900-4954

The Table below includes the tests for 11 Drugs of Abuse, 17 Opioids & metabolites and 16 Benzodiazepines & metabolites included in the new Pain Management Drug Analysis procedure.

DOA	OA OPIOIDS		BENZODIAZEPINES	
Benzoylecognine	Buprenorphine	Naloxone	Alprazolam	Desalkylflurazepam
Amphetamine	nor-Buprenorphine	Naltrexone	α-hydroxyalprazolam	2-Hydroxyethylflurazepam
Methamphetamine	Codeine	Oxycodone	7-aminoclonazepam	α-Hydroxytriazolam
MDMA	Dihydrocodeine	Oxymorphone	Chlordiazepoxide	Lorazepam
MDA	Fentanyl	Tapentadol	Clobazam	Midazolam
6-MAM	nor-Fentanyl	N-desmethyltapentadol	Diazepam	α-hydroxymidazolam
Phentermine	Hydrocodone	<i>cis</i> -tramadol	nor-Diazepam	Oxazepam
РСР	Morphine	N-desmethyltramadol	Estazolam	Temazepam
ТНС	Hydromorphone	anted a new Pain Manifest	melani bas balatikas	e foxenogi laboratori ha
Methadone	na presentes de la reliva. Abie ócelente		o y dan du stat artan a bos atom V astroite	tere ne via provintitorio tra. To south 12 onlineton suuti
EDDP				